LEO Pharma is owned by the LEO Foundation. The LEO Foundation is an independent commercial foundation with the objective to develop LEO Pharma as an independent pharmaceutical company.
The objective of LEO Pharma is to develop, manufacture and market safe and efficacious drugs on the basis of substantial and growing earnings... Read more
News
FDA Approves Taclonex Scalp® - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis. Warner Chilcott and LEO Pharma announced 12 May that the FDA has approved...
Financial figures 2007 With an increasing turnover of DKK 5,245.9 million, LEO Pharma achieved satisfactory results on its way into 2008 – the year of the company’s 100 years’ anniversary.
LEO Pharma achieved a fine result in 2007 Psoriasis is a chronic skin disease, which seriously affects the patients’ quality of life and their psychological and physical well-being...
Manufacturing at LEO Learn more about the LEO Pharma production plants in Denmark, France and Ireland.
Wednesday 14 May 2008
Jobs
07-05-2008 - Research Scientist for pre-formulation and... We offer an exciting position in the Department of Spectroscopy and Physical Chemistry. The position involves activities in the discovery process...
/(E100A3479E2D2A0D9B0B186CE59A1ABD)/$File/menuHome.gif){kind=small}
/(E100A3479E2D2A0D9B0B186CE59A1ABD)/$File/menuIndicator2.gif){kind=small}
/(E100A3479E2D2A0D9B0B186CE59A1ABD)/$File/documentIcon.gif){kind=small}
News
/(E100A3479E2D2A0D9B0B186CE59A1ABD)/$File/dotted_line.gif){kind=small}
Sitemap